ArticleCancer2018

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

Eileen M O'Reilly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.